ASSOCIATION BETWEEN CLINICAL MANIFESTATIONS OF GOUT AND PATIENT REPORTED OUTCOME MEASURES: RESULTS OF A REAL-WORLD SURVEY IN THE UNITED STATES
Author(s)
Andrew Sulich, MD1, Menaka Bhor, PhD2, James Hawthorne, PharmD3, Emily Goddard, MChem4, Molly Edwards, BSc4, Alastair Hinds, BSc4, Ted Mikuls, MD5;
1Ascension Saint John Medical Center, Detroit, MI, USA, 2Sobi, Kingwood, TX, USA, 3Sobi, Auburn, MA, USA, 4Adelphi Real World, Bollington, United Kingdom, 5University of Nebraska Medical Center, Omaha, NE, USA
1Ascension Saint John Medical Center, Detroit, MI, USA, 2Sobi, Kingwood, TX, USA, 3Sobi, Auburn, MA, USA, 4Adelphi Real World, Bollington, United Kingdom, 5University of Nebraska Medical Center, Omaha, NE, USA
OBJECTIVES: Gout is a common inflammatory arthritis that significantly impacts patients’ quality of life (QoL). Data on links between patient-reported outcomes (PROs) and clinical indicators of disease burden remain limited. This analysis evaluated the association between PROs and clinical manifestations in gout.
METHODS: Data were extracted from the Adelphi Real World Gout Disease Specific Programme™, a cross-sectional survey of physicians (rheumatologists and primary-care physicians (PCPs)) and their patients with gout in the United States between August 2023 - August 2024. Physicians reported patients’ serum urate (sUA), tophi, and flares at most recent consultation. Patients completed the EQ-5D-5L (scale 0-1, 0=worst health state), Health Assessment Questionnaire - Disability Index (HAQ-DI; scale 0-3, 3=worst QoL) and Work Productivity and Activity Impairment (WPAI; scale 0-100% impairment) questionnaire. Linear regression analysis examined relationships between clinical manifestations and PROs, controlling for patient age and disease duration.
RESULTS: Data were extracted for 162 patients (n=77 rheumatologist-managed, n=85 PCP-managed). The patients had a mean (standard deviation) age of 56.7 (16.2) years, 73% were male, and mean disease duration was 6.6 (7.3) years with mean sUA 6.4 (2.1) mg/dL at data collection. A 1mg/dL higher sUA was significantly associated with a worse EQ-5D (coefficient: -0.04), worse HAQ-DI (coeff: 0.10), and greater percentage activity impairment (coeff: 3.68; all p<0.05). Compared to patients with no tophi, those with ≥1 tophi reported significantly greater impairment with a worse EQ-5D (coeff: -0.15), worse HAQ-DI (coeff: 0.41), and greater percentage activity impairment (coeff: 15.83; all p<0.05). Compared to those with <2 flares in the prior 12 months, patients with ≥2 flares reported significantly greater impairment with a worse EQ-5D (coeff: -0.20), worse HAQ-DI (coeff: 0.52) and greater percentage activity impairment (coeff: 20.86; all p<0.05).
CONCLUSIONS: The significant association between disease progression and worsening of PROs suggests treatments that reduce gout clinical manifestations may also improve patients' QoL.
METHODS: Data were extracted from the Adelphi Real World Gout Disease Specific Programme™, a cross-sectional survey of physicians (rheumatologists and primary-care physicians (PCPs)) and their patients with gout in the United States between August 2023 - August 2024. Physicians reported patients’ serum urate (sUA), tophi, and flares at most recent consultation. Patients completed the EQ-5D-5L (scale 0-1, 0=worst health state), Health Assessment Questionnaire - Disability Index (HAQ-DI; scale 0-3, 3=worst QoL) and Work Productivity and Activity Impairment (WPAI; scale 0-100% impairment) questionnaire. Linear regression analysis examined relationships between clinical manifestations and PROs, controlling for patient age and disease duration.
RESULTS: Data were extracted for 162 patients (n=77 rheumatologist-managed, n=85 PCP-managed). The patients had a mean (standard deviation) age of 56.7 (16.2) years, 73% were male, and mean disease duration was 6.6 (7.3) years with mean sUA 6.4 (2.1) mg/dL at data collection. A 1mg/dL higher sUA was significantly associated with a worse EQ-5D (coefficient: -0.04), worse HAQ-DI (coeff: 0.10), and greater percentage activity impairment (coeff: 3.68; all p<0.05). Compared to patients with no tophi, those with ≥1 tophi reported significantly greater impairment with a worse EQ-5D (coeff: -0.15), worse HAQ-DI (coeff: 0.41), and greater percentage activity impairment (coeff: 15.83; all p<0.05). Compared to those with <2 flares in the prior 12 months, patients with ≥2 flares reported significantly greater impairment with a worse EQ-5D (coeff: -0.20), worse HAQ-DI (coeff: 0.52) and greater percentage activity impairment (coeff: 20.86; all p<0.05).
CONCLUSIONS: The significant association between disease progression and worsening of PROs suggests treatments that reduce gout clinical manifestations may also improve patients' QoL.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR50
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)